About HAYA Therapeutics

At HAYA Therapeutics, we are revolutionizing RNA-guided genome-targeting therapies to treat fibrosis, heart failure, and other serious chronic diseases associated with aging. Our innovative platformleverageslong non-coding RNAs (lncRNAs) - key regulators within the dark matter of the genome - to develop first-in-class, highly specific therapies that reprogram disease-driving cell states into a healthy and resilient state, tackling disease at its roots.

Following the successful close of our Series A financing, HAYA is well-positioned to advance our pipeline and execute on key scientific and operational milestones, including the advancement of HAYA’s lead program, HTX-001, toward the clinic for the treatment of non-obstructive hypertrophic cardiomyopathy (nHCM).

In recognition of our scientific innovation and potential global impact, we have been named one of the 100 early-stage companies selected for the World Economic Forum’s 2025...